GIS

Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures

EAST HANOVER, N.J.--(BUSINESS WIRE)--Jul 11, 2007 - Since the May2007 release of a New England Journal of Medicine (NEJM) reportthat Avandia users are 43 percent more likely to suffer a heartattack and 67 percent more likely to die of cardiovascular causesthan non-users of Avandia, it is no surprise that physicians intendto switch many type 2 diabetes patients from Avandia to therapiesbelie...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze byAlmost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007/PRNewswire-FirstCall/ -- Abbott and MedImmune today announcedresults of a new study, published in the July issue of Journal ofPediatrics, showing that treatment with Synagis(R) (palivizumab)may reduce recurrent wheezing in premature infants by almosthalf.<...

Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study

RALEIGH, N.C.--(BUSINESS WIRE)--Jun 18, 2007 - SalixPharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successfulcompletion and outcome of its Phase III registration trial toevaluate the safety and efficacy of a new 1100 mg tabletformulation of balsalazide disodium (balsalazide tablets).Balsalazide disodium is the active ingredient in COLAZAL(R)Capsules 750 mg, an anti-inflammatory dru...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented theresults of a study conducted by researchers at the University ofChicago and ApoCell at the 2007 annual meeting of the AmericanSociety of Clinical Oncology (ASCO) held in Chicago in early June.The study showed that ApoCell's advanced pharmacodynamic biomarkerassay technology provides reliable predictive data of clinicalrespon...

Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting

Data From the Companies' Novel Heat Shock Protein 90 InhibitorReveal Further Evidence of Safety, Tolerability, and BiologicalActivity CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIMENEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) andMedImmune, Inc. (Nasdaq:MEDI) today announced updated interimresults from a Phase I clinical trial of the companies' heat shockpr...

ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents

Study highlights importance of antiplatelet therapy compliance NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced results from an analysis of more than 7,000 patients fromits ARRIVE 1 and 2 registries, designed to assess the performanceof the TAXUS(R) Express2(TM) paclitaxel- eluting coronary stentsystem in "real-world" p...

ANX-201 Drug Combination Demonstrates Synergistic Activity Against Human and Bird Flu Viruses

ADVENTRX Presents Results at International Conference on AntiviralResearch SAN DIEGO, May 03, 2007 /PRNewswire-FirstCall/ -- ADVENTRXPharmaceuticals, Inc. , a biopharmaceutical research anddevelopment company focused on commercializing proprietary productcandidates for the treatment of cancer and infectious diseases,announced today that it presented results demonstrating synergisticactiv...

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

CALGARY, April 17, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. ("Oncolytics") announces that a poster by Dr. MaureenE. Lane et al. of , New York, entitled "In Vivo Synergy betweenOncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116Xenografts" is scheduled to be presented today at the AmericanAssociation for Cancer Research (AACR) Annual Meeting in LosAngeles, CA. The m...

Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study

* Glivec found to dramatically reduce the risk of cancerreturning after surgery for Kit-positive gastrointestinal stromaltumors (GIST) * Patients receiving placebo in this trial will now be offeredGlivec * Global regulatory submissions planned for use of Glivec asadjuvant therapy in GIST patients following surgery to removeprimary tumor * Glivec already approved as ef...

Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study

- Gleevec found to dramatically reduce the risk of cancer returningafter surgery for Kit-positive gastrointestinal stromal tumors(GIST) EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ -- Investigatorswill begin offering Gleevec(R) (imatinib mesylate)* tablets topatients receiving placebo in a major North American clinical trialafter an interim analysis showed participants with Kit-positiv...

Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- A large patientregistry of "real world" uses for the CYPHER(R) Sirolimus-elutingCoronary Stent reported favorable safety and efficacy outcomes attwo-year follow-up, according to clinical investigators at the ofCardiology's 56th Annual Scientific Session (ACC.07). The MATRIX Registry is a prospective, single-arm study designedto evaluate t...

REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis

- The Reduction of Atherothrombosis for Continued Health(REACH) PARIS, March 20, 2007 /PRNewswire/ --The REACH Registry 1-yearresults paper published today in the Journal of the AmericanMedical Association (JAMA) show that outpatients withatherothrombosis have a surprisingly high risk of death or majorcardiovascular illness, especially if more than...